跳至主要内容
临床试验/NCT04910464
NCT04910464招募中3 期

Could Early Tranexamic Acid Safely Serve as an Anti-inflammatory Treatment for Patients With Sepsis? A Randomized Double Blind Controlled Trial

Assiut University1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2021年6月5日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
招募中
入组人数
80
试验地点
1
主要终点
ICU mortality

研究概览

简要总结

In this study, our aim is to investigate the role tranexamic acid in modulating inflammation in patients with sepsis.

详细描述

A written informed consent will be taken from the patients or their relatives.Patients will be assigned randomly to two groups (40 subjects each) with qSOFA ≥2.

In (Group T) administer 1 gram of tranexamic acid (TXA) in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of tranexamic acid (TXA) IV over 8 hours in 0.9% normal saline for the first 3 days. In (Group C) administer the same volume (100 ml normal saline)and same duration (first three days)for controlled patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults (age 18-65 years) of American society of anesthesiologists (ASA) I-II who will be diagnosed with sepsis by qSOFA ≥2
  • & needed ICU admission.

排除标准

  • Chronic renal failure
  • Liver cirrhosis
  • Bleeding disorders or current anticoagulant therapy
  • Pregnancy or breastfeeding
  • Impaired color vision
  • Severe vascular ischemia, history of venous thrombosis & pulmonary embolism
  • Long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs not discontinued before ICU admission
  • Allergy to tranexamic acid (TXA)

研究组 & 干预措施

Tranexamic acid

Experimental

Give 1 gram of TXA in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of TXA IV over 8 hours in 0.9% normal saline for the first 3 days.

干预措施: Tranexamic acid (Drug)

Saline placebo

Placebo Comparator

Give the same volume (100 ml normal saline) and same duration (first three days).

干预措施: 0.9% saline (Other)

结局指标

主要结局

ICU mortality

时间窗: 7days

Short-term ICU mortality within 7days of admission and intervention

次要结局

  • ICU stay(7 days)
  • Glasgow coma scale (GCS)(5 days)
  • Neutrophil/lymphocyte ratio (NLR)(4 days)
  • Interleukin-6 (IL-6) serum level(4 days)
  • Length of hospitalization(7 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Omar Makram Soliman

Lecturer of anesthesia and ICU

Assiut University

研究点 (1)

Loading locations...

相似试验